Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers

Pharmacogenetics and Genomics
Euitae KimSang-Goo Shin

Abstract

The Taq1A polymorphism in the dopamine D2 receptor (DRD2) gene has been reported to be associated with the pharmacodynamics of antipsychotic drugs. We investigated the metabolic response of glucose in the brain to aripiprazole in relation to the DRD2 Taq1A polymorphism. Twenty healthy male volunteers were recruited and were divided into two groups of 10 participants, according to their DRD2 genotypes (A1A1, n=10; A2A2, n=10). The volunteers received single oral doses of aripiprazole (10 mg) and a placebo, following a single-blind, placebo-controlled, randomized, two-way crossover study design. Brain glucose metabolism was assessed using positron emission tomography, scanned with 18F-fluorodeoxyglucose 12 h after the administration of the drug or placebo. In voxel-based analysis using SPM2, volunteers with the A2A2 genotype showed decreased metabolism in the right middle frontal gyrus, the left middle and inferior frontal gyrus, the right and left inferior temporal gyrus, and the right cingulate gyrus, and increased metabolism in the pons. In contrast, volunteers with the A1A1 genotype exhibited increased metabolism in the right caudate head, and no brain region showed decreased metabolism. In a region-of-interest analysis, sign...Continue Reading

References

Jun 1, 1985·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·L E DeLisiM S Buchsbaum
May 1, 1994·The American Journal of Psychiatry·E J BartlettA Wolkin
Aug 15, 1993·Biological Psychiatry·C L Barr, K K Kidd
Jan 1, 1996·The American Journal of Psychiatry·H H HolcombC A Tamminga
Dec 24, 2002·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Ernest P Noble
Jan 28, 2004·The Journal of Clinical Psychiatry·Peter Brieger
Feb 21, 2004·The Journal of Clinical Psychiatry·John R DeQuardo
Apr 23, 2004·International Clinical Psychopharmacology·Sriram RamaswamyFrederick Petty
May 4, 2004·The American Journal of Psychiatry·Anil K MalhotraJames L Kennedy
Jul 2, 2004·The American Journal of Psychiatry·Sebastian Hartter
Jul 2, 2004·The American Journal of Psychiatry·Roy R Reeves, James E Mack
Sep 9, 2004·Acta Psychiatrica Scandinavica·K HillP J McKenna
Dec 17, 2004·International Clinical Psychopharmacology·Vicente MolinaManuel Desco
Feb 8, 2005·Psychopharmacology·Andrew C Harris, Jonathan C Gewirtz
Apr 6, 2005·Archives of General Psychiatry·Jussi HirvonenTyrone D Cannon
Feb 21, 2006·The International Journal of Neuropsychopharmacology·Michele Raja

❮ Previous
Next ❯

Citations

Sep 13, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Jun Soo KwonUNKNOWN APLUS study group
Jun 27, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Norio Yasui-FurukoriSunao Kaneko
May 1, 2020·Frontiers in Psychiatry·Andrea MiuliMassimo di Giannantonio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here